A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.

Study NCT00315731 Information provided by GlaxoSmithKline

First Received: April 17, 2006 Last Updated: October 21, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	November 2016
Primary Completion Date:	December 2006 (Final data collection date for primary outcome measure)